<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83059">
  <stage>Registered</stage>
  <submitdate>11/08/2008</submitdate>
  <approvaldate>26/08/2008</approvaldate>
  <actrnumber>ACTRN12608000428369</actrnumber>
  <trial_identification>
    <studytitle>The effect of the glucagon-like peptide-1 analogue, exenatide, on duodenal motility and flow events, and small intestinal transit in healthy humans and type 2 diabetes mellitus.</studytitle>
    <scientifictitle>The effect of the glucagon-like peptide-1 analogue, exenatide, on duodenal motility and flow events, and small intestinal transit in healthy humans and type 2 diabetes mellitus.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Type 2 diabetes</healthcondition>
    <healthcondition>Small intestinal motility</healthcondition>
    <healthcondition>Glucose absorption</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Normal oral and gastrointestinal development and function</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Each subject will be studied on 2 occasions in a double-blind, randomised crossover design, separated by at least 3 days. On both days, subjects will receive an intraduodenal glucose infusion at a rate of 3 kcal/min from t = 0 to 60 min. On one day, an intravenous (IV) infusion of exenatide will be administered (50 ng/min between t = -30 to 0 min, then 25 ng/min between 0 and 240 min). On the other day, IV saline 0.9% will be administered between t = -30 and 240 min) .</interventions>
    <comparator>IV 0.9% saline; appearance identical to exenatide infusion.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Frequency of duodenal pressure waves and flow events, measured by manometry and impedance</outcome>
      <timepoint>15 min periods from t = 0 to 240 min</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Small intestinal transit, measured by scintigraphy</outcome>
      <timepoint>Every 15 min from 0 to 60 min, then every 30 min from 60 to 240 min</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Absorption of the glucose analog, 3-O-methylglucose (3-OMG), as assessed by plasma concentrations of 3-OMG</outcome>
      <timepoint>t = 0, 10, 20, 30, 40, 50, 60, 90, 120, 180, and 240 min</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy subjects:
1. Body mass index (BMI) 19 - 25 kg/m2
Type 2 diabetic patients:
1. Body mass index (BMI) 19 - 35 kg/m2
2. Type 2 diabetes (World Health Organisation (WHO) criteria) managed by diet alone (i.e no oral hypoglycaemic drugs or insulin)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>History of gastrointestinal surgery (except appendicectomy)
1. Medication which may affect gastrointestinal motor function, specifically: opiates, anticholinergics, levodopa, calcium-channel antagonists, beta blockers, clonidine, nitrates, tricyclic antidepressants, selective serotonin re-uptake inhibitors, phosphodiesterase type 5 inhibitors, sumatriptan, metoclopramide, domperidone, cisapride, tegaserod, erythromycin
2. Other significant illness, including epilepsy, cardiovascular or respiratory disease
3. Pregnancy or lactation
4. Evidence of drug abuse, consumption of more than 20 g alcohol or 10 cigarettes per day
5. Regular gastrointestinal symptoms (as assessed by a validated upper gastrointestinal symptom questionnaire)
6. Autonomic nerve damage (as assessed by standardised cardiovascular reflex tests)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed opaque envelopes</concealment>
    <sequence>Computer-generated random number table</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>15/09/2008</anticipatedstartdate>
    <actualstartdate>5/12/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate>28/03/2014</actualenddate>
    <samplesize>24</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Royal Adelaide Hospital</primarysponsorname>
    <primarysponsoraddress>Royal Adelaide Hospital, North Terrace, Adelaide SA 5000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Eli Lilly Australia</fundingname>
      <fundingaddress>112 Wharf Road, West Ryde  NSW  2114</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Glucagon-like peptide-1 (GLP-1) is a naturally occurring hormone in the human body that has the effect of stimulating insulin secretion and slowing stomach emptying, helping to limit the rise in blood glucose after a meal. Exenetide is a drug that mimics GLP-1, and has recently been approved in Australia for the treatment of diabetes. However, there is little information on how GLP-1 can affect the small intestine. The aim of this study is to see what effect exenatide has on the contractions and flow of contents inside the small intestine and how it affects glucose absorption. The findings will help us understand how sugar is absorbed in the small intestine in health and in people with diabetes, and whether the effects of exenatide on small intestinal function would benefit people with diabetes.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital Human Research Ethics Committee</ethicname>
      <ethicaddress>Level 3, Hanson Institute
Royal Adelaide Hospital,
North Terrace, Adelaide SA 5000</ethicaddress>
      <ethicapprovaldate>10/04/2008</ethicapprovaldate>
      <hrec>080210a</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>A/Prof Chris Rayner</name>
      <address>Discipline of Medicine
Royal Adelaide Hospital
North Terrace
Adelaide SA 5000</address>
      <phone>08 8222 2916</phone>
      <fax>08 8223 3870</fax>
      <email>chris.rayner@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>A/Prof Chris Rayner</name>
      <address>Discipline of Medicine
Royal Adelaide Hospital
North Terrace
Adelaide SA 5000</address>
      <phone>08 8222 2916</phone>
      <fax>08 8223 3870</fax>
      <email>chris.rayner@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>A/Prof Chris Rayner</name>
      <address>Discipline of Medicine
Royal Adelaide Hospital
North Terrace
Adelaide SA 5000</address>
      <phone>08 8222 2916</phone>
      <fax>08 8223 3870</fax>
      <email>chris.rayner@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Chris Rayner</name>
      <address>Discipline of Medicine Royal Adelaide Hospital North Terrace Adelaide SA 5000</address>
      <phone>+61 8 82222916</phone>
      <fax />
      <email>chris.rayner@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>